MARKET

KTRA

KTRA

Kintara Therapeutics Inc
NASDAQ
6.84
-0.15
-2.15%
After Hours: 7.12 +0.28 +4.09% 17:56 02/03 EST
OPEN
7.21
PREV CLOSE
6.99
HIGH
7.25
LOW
6.70
VOLUME
10.55K
TURNOVER
0
52 WEEK HIGH
42.00
52 WEEK LOW
3.502
MARKET CAP
11.05M
P/E (TTM)
-0.3555
1D
5D
1M
3M
1Y
5Y
KALA, THMO and KTRA among mid-day movers
Seeking Alpha · 01/26 17:43
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 01/26 17:31
Analyzing Kintara Therapeutics's Short Interest
Benzinga · 01/03 15:04
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
Benzinga · 12/15/2022 18:28
Why Kintara Therapeutics Stock Is Seeing Blue Skies Thursday
Benzinga · 12/15/2022 16:49
BRIEF-Kintara Therapeutics Receives FDA's 'Orphan Drug' Status For Val-083 For Treatment Of Diffuse Intrinsic Pontine Glioma
Reuters · 12/15/2022 14:17
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 12/02/2022 17:32
10 Pump and Dump Stocks Hedge Funds Like
In this article, we discuss the 10 pump and dump stocks hedge funds like. If you want to read about some more pump and dump stocks, go directly to 5 Pump and Dump Stocks Hedge Funds Like. The influx of retail investors on the stock market in recent months ...
Insider Monkey · 12/02/2022 14:47
More
About KTRA
Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to available therapies, with particular focus on orphan cancer indications. The Company’s two lead candidates include VAL-083 and REM-001. Its VAL-083 is a novel, validated, deoxyribonucleic acid (DNA) targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG) The Company’s REM-001, a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC); basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients.

Webull offers kinds of Kintara Therapeutics Inc stock information, including NASDAQ:KTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KTRA stock methods without spending real money on the virtual paper trading platform.